Michael Edmund Luggen MD

Professor of Medicine, University Cincinnati

311 Straight StCincinnati, OH 45219
Phone+1 513-559-2898
Fax+1 513-475-5415

Dr. Luggen is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Luggen's full profile Already have an account?

Education & Training

University of Cincinnati Medical Center/College of MedicineFellowship, Allergy and Immunology, 1980 - 1982
University of Cincinnati Medical Center/College of MedicineResidency, Internal Medicine, 1974 - 1977
Columbia University Vagelos College of Physicians and SurgeonsClass of 1974

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

OH State Medical License 1977 - 2028
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Rheumatology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2017

Clinical Trials

Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
COMPLETED
PHASE2
Comparative Efficacy and Safety Study of GP2015 and Enbrel® in Patients With Rheumatoid Arthritis Start of enrollment: 2015 Feb 21
COMPLETED
PHASE3

Publications & Presentations

PubMed

A Phase 3 Trial of Brepocitinib in Dermatomyositis.
Ruth Ann Vleugels, Julie J Paik, Iazsmin Bauer Ventura, Aaron R Mangold, Prateek C Gandiga
The New England Journal of Medicine. 2026-05-14
The impact of comorbidities on the efficacy of IL-6 inhibitor olokizumab compared to adalimumab in a randomized controlled trial.
Eugen Feist, Michael E Luggen, Evgeny L Nasonov, Sergey S Yakushin, Daria V Bukhanova
Arthritis Research & Therapy. 2025-11-14
1 citations
Diagnostic Utility of Antibodies to Extractable Nuclear Antigens in the Absence of Positive Antinuclear Antibodies.
Jason Huang, Bassel B Dargham, Michael Luggen
Cureus. 2025-09-01

Press Mentions

R-pharm’s Rheumatoid Arthritis Drug, Olokizumab, Offers Significant Benefits in Phase 3 CREDO TrialMay 20th, 2021

Grant Support

Sulfasalazine In The Treatment Of Ankylosing SpondylitisNational Center For Research Resources1990
Early Undifferentiated Connective Tissue DiseaseNational Center For Research Resources1990